These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 24281375

  • 1. Asymmetric dimethylarginine and critical illness.
    Brinkmann SJ, de Boer MC, Buijs N, van Leeuwen PA.
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):90-7. PubMed ID: 24281375
    [Abstract] [Full Text] [Related]

  • 2. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA.
    JPEN J Parenter Enteral Nutr; 2008 Jan; 32(6):613-21. PubMed ID: 18974239
    [Abstract] [Full Text] [Related]

  • 3. Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patients.
    Koch A, Weiskirchen R, Kunze J, Dückers H, Bruensing J, Buendgens L, Matthes M, Luedde T, Trautwein C, Tacke F.
    J Crit Care; 2013 Dec; 28(6):947-53. PubMed ID: 23953490
    [Abstract] [Full Text] [Related]

  • 4. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
    Liu X, Hou L, Xu D, Chen A, Yang L, Zhuang Y, Xu Y, Fassett JT, Chen Y.
    Nitric Oxide; 2016 Apr 01; 54():73-81. PubMed ID: 26923818
    [Abstract] [Full Text] [Related]

  • 5. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
    Blackwell S.
    Ann Clin Biochem; 2010 Jan 01; 47(Pt 1):17-28. PubMed ID: 19940201
    [Abstract] [Full Text] [Related]

  • 6. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.
    Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M.
    World J Gastroenterol; 2015 May 07; 21(17):5131-7. PubMed ID: 25954086
    [Abstract] [Full Text] [Related]

  • 7. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.
    Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA.
    Clin Nutr; 2003 Feb 07; 22(1):23-30. PubMed ID: 12553946
    [Abstract] [Full Text] [Related]

  • 8. ADMA and hyperhomocysteinemia.
    Dayal S, Lentz SR.
    Vasc Med; 2005 Jul 07; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [Abstract] [Full Text] [Related]

  • 9. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R.
    Vasc Med; 2005 Jul 07; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [Abstract] [Full Text] [Related]

  • 10. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
    Böger RH.
    Vasc Med; 2005 Jul 07; 10 Suppl 1():S19-25. PubMed ID: 16444865
    [Abstract] [Full Text] [Related]

  • 11. ADMA: its role in vascular disease.
    Cooke JP.
    Vasc Med; 2005 Jul 07; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [Abstract] [Full Text] [Related]

  • 12. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
    Visser M, Paulus WJ, Vermeulen MA, Richir MC, Davids M, Wisselink W, de Mol BA, van Leeuwen PA.
    Eur J Heart Fail; 2010 Dec 07; 12(12):1274-81. PubMed ID: 20923854
    [Abstract] [Full Text] [Related]

  • 13. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury.
    Stühlinger MC, Conci E, Haubner BJ, Stocker EM, Schwaighofer J, Cooke JP, Tsao PS, Pachinger O, Metzler B.
    Cardiovasc Res; 2007 Jul 15; 75(2):417-25. PubMed ID: 17559823
    [Abstract] [Full Text] [Related]

  • 14. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
    Böger RH.
    J Nutr; 2004 Oct 15; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
    [Abstract] [Full Text] [Related]

  • 15. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness.
    Davids M, Richir MC, Visser M, Ellger B, van den Berghe G, van Leeuwen PA, Teerlink T.
    Metabolism; 2012 Apr 15; 61(4):482-90. PubMed ID: 22000584
    [Abstract] [Full Text] [Related]

  • 16. The clinical significance of asymmetric dimethylarginine.
    Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA.
    Annu Rev Nutr; 2006 Apr 15; 26():203-28. PubMed ID: 16848705
    [Abstract] [Full Text] [Related]

  • 17. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B, Möller-Ehrlich K, Kress T, Kniepert J, Schwedhelm E, Böger RH, Wanner C, Sauvant C, Schneider R.
    Transl Res; 2013 Aug 15; 162(2):67-76. PubMed ID: 23707198
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.
    Leiper J, Nandi M.
    Nat Rev Drug Discov; 2011 Apr 15; 10(4):277-91. PubMed ID: 21455237
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.